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Abstract
 .The goal of this study was to examine the mechanisms of transport of g-aminobutyric acid GABA in the choroid
plexus. Choroid plexus slices from the rabbit were depleted of ATP with 2,4-dinitrophenol. GABA accumulated in the
choroid plexus slices in a concentrative manner in the presence of an inwardly-directed Naq gradient. Uptake occurred in
the presence of Cly; replacement of Cly with gluconate abolished uptake. SCNy, NOy or Bry were able to support uptake3
y  . in the absence of Cl to a significant extent 80, 68 and 61% of control, respectively . GABA uptake was saturable K ofm
. q  .37"8.5 mM, V of 409"43 nmolrgrmin . Na -driven GABA uptake was inhibited by b-alanine IC s22.9 mMmax 50
 .  .and hypotaurine IC s21.9 mM but less potently by nipecotic acid IC s244 mM and hydroxy-nipecotic acid50 50
 .  . w xIC s284 mM . Betaine, L- 2,4 -diaminobutyric acid, guvacine and 4,5,6,7-tetrahydroisoxazolo 4,5-c pyridin-3-ol were50
 . q  .weak inhibitors IC )500 mM . GABA inhibited Na -driven uptake of taurine IC s230 mM ; taurine, however, did50 50
 .not inhibit GABA uptake IC )1 mM . RT–PCR, using degenerate primers for cloned GABA transporters, did not result50
in the amplification of a band from rat choroid plexus RNA. The location of the choroid plexus in the ventricles of the
brain, and its role in the secretion of the cerebrospinal fluid, suggest a role for the choroid plexus Naq-GABA transporter in
the disposition of GABA in the brain. q 1997 Elsevier Science B.V.
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1. Introduction
 .g-Aminobutyric acid GABA is a neurotrans-
mitter amino acid which is found throughout the
central nervous system of vertebrates, formed in neu-
ronal cells by the decarboxylation of glutamic acid
and further metabolized by GABA-a-keto-glutarate
transaminase. Upon release into the synaptic cleft,
GABA binds to post-synaptic GABA receptors andA
elicits a neuroinhibitory response by activating Cly
channels. Naq and Cly-coupled GABA transporters
terminate the actions of GABA by mediating its rapid
removal from the synapse. Previously, it was pro-
posed that there were two types of GABA trans-
porters based on their different sensitivity to b-alanine
w x1,2 . The recent cloning and heterologous expression
of GABA transporters has made it clear that multiple
subtypes of this transporter exist, and that these can
be differentiated on the basis of pharmacological
w xsensitivities to GABA transport inhibitors 3–7 .
Studies of GABA transport have focused on neu-
w xronal and glial cells 1,2,8,9 . In addition, GABA
transport has been described in the epithelia of the
w x w x w x w xretina 10 , stomach 11 , duodenum 12 , kidney 13
w xand oviduct 14 , although the significance of these
processes is generally less clear. The choroid plexus
epithelium, which secretes the cerebrospinal fluid
 .CSF , is a major site for transport mechanisms into
and out of the brain via the ventricles of the brain
w x15–17 . The location of the choroid plexus within
the ventricles of the brain and its production of the
CSF suggest a physiological role for the choroid
plexus in maintaining the protected milieu of the
brain. A previous study, in vivo, suggested bi-direc-
tional transport of GABA between the CSF and
blood; the transport of GABA from the CSF to blood
was inhibited by probenecid an inhibitor of the
. w xorganic anion transporter 18 . In addition, an early,
preliminary in vitro study reported saturable uptake
w xof GABA in the choroid plexus of the cat 19 ;
however, the mechanisms of the uptake were not
characterized.
The goal of this study was to determine the mecha-
nisms of GABA transport in the choroid plexus. Our
data provide the first evidence for a Naq-dependent
GABA transporter in the choroid plexus. The choroid
plexus is increasingly being recognized as a target
w x w xtissue for hormones 20 and neurotransmitters 21 .
The GABA transporter in the choroid plexus may
play a role in CSF production or in maintaining
homeostasis of GABA in the CSF and ultimately in
the extracellular fluids of the brain.
2. Methods
2.1. Preparation of ATP-depleted choroid plexus
Choroid plexus was obtained from brains of New
Zealand White rabbits and depleted of ATP using a
modification of the method of Carter-Su and Kim-
w x w xmich 22 that has been described previously 23–25 .
The animals were anesthetized with ketamine 5
.mgrkg and decapitated. The choroid plexus was
quickly removed from the lateral ventricles and placed
in one of the following buffers at room temperature
 .  .  .  .mM : KCl 120 , mannitol 40 , and HEPES 25 or
 .  .  .NaCl 120 , mannitol 40 , and HEPES 25 ; the pH
of each buffer was adjusted to 7.4 with 1 M Tris.
Each choroid plexus was cut into 2–3-mm pieces and
depleted of ATP by placing them in appropriate
pre-loading buffers containing 250 mM 2,4-dinitro-
 .phenol DNP , for 20 min at 378C. Following ATP-
depletion, all tissue pieces in the DNP-containing
buffer were stored on ice until the start of the uptake
studies. The tissue pieces were removed from the
pre-loading buffer and blotted gently on laboratory
tissue. Uptake commenced with placing the pieces in
the appropriate uptake medium.
2.2. Uptake studies
Uptake of GABA into the choroid plexus was
studied by incubating the tissue in 140 ml of uptake
 . w3 x medium 378C , which contained H GABA 0.01
. w14 x  .mM , C mannitol 17.9 mM and unlabeled GABA
 . 1 mM , in appropriate buffer indicated in the figure
. legends . The uptake medium contained DNP 250
.mM to ensure continued depletion of ATP. Uptake
in the presence of Naq increased linearly and repro-
 .ducibly with time, until 2.5 min Fig. 1 . Therefore,
uptake was determined at 1 min in all subsequent
studies.
For Michaelis–Menten studies, the uptake medium
w3 x w14 xcontained H GABA and C mannitol and different
amounts of unlabeled GABA to obtain the indicated
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.GABA concentrations . For IC studies, the uptake50
w3 x w14 xmedium consisted of H GABA, C mannitol, un-
 .labeled GABA 1 mM and different amounts of
unlabeled compounds. Data for both Michaelis–
Menten and inhibition studies were generated by
measuring GABA uptake into the tissue at 1 min.
Uptake was terminated in each choroid plexus
tissue piece by removing it from the uptake medium
and blotting it gently on laboratory tissue. Prelimi-
nary experiments showed that rinsing tissue in ice
cold buffer versus blotting on laboratory tissue had
equal effect in stopping the uptake reaction. The
blotted tissue piece was placed on a pre-weighed
piece of aluminum foil, dried under an IR-lamp
 .heater approximately 15 cm away from tissue for 1
h, and then weighed to calculate the net dry tissue
weight. The tissue was carefully detached from the
foil using forceps and digested in 50 ml of 3 M KOH
solution in a liquid scintillation counting vial. After
dissolution was complete, 50 ml of 3 M HCl solution
was added to neutralize the KOH. The corresponding
aluminum foil was then added to the vials and the
tissue-associated radioactivity was determined by liq-
uid scintillation. In addition, the uptake medium 50
.ml was sampled and added to separate vials for
liquid scintillation counting. Quantitation of 14C and
3H was done by dual isotope liquid scintillation
counting on a Beckman Model 1801 liquid scintilla-
 .tion counter Beckman Instruments, Fullerton, CA .
Counting efficiency of 3H ranged from 45% to 47%
and that of 14C ranged from 92% to 94%.
Uptake of taurine into the choroid plexus pieces
was examined in a manner identical to GABA except
that, in this case, the uptake medium contained
w3 x  . w14 x  .H taurine 0.0391 mM , C mannitol 17.9 mM
and different amounts of GABA. Taurine uptake into
w xthe tissue was measured at 15 min 24 .
2.3. Re˝erse transcriptase–polymerase chain reac-
( )tion RT–PCR
Specific oligonucleotide primers corresponding to
nucleotides 242–276 and 1108–1139 of GAT-
3rGAT-B were synthesized UCSF Biomolecular
.Resource Center ; the sequences were: sense, ACAA-
GAACGGCGGAGGGGCATTCCTGATTCCTTA
and antisense, ATGAAAGCCAGTCCAGGACCT-
GATTCTGCCA. Degenerate oligonucleotide primers,
w xpreviously described 5 , corresponding to transmem-
brane domains II and VI of GAT-1 protein, were
 .synthesized UCSF Biomolecular Resource Center ;
the sequences were: sense, CCGCTCGAGAA-
 .  .  .  .GAACGG CrT GG CrT GG CrT GC CrT TTC-
 .  .  .  .CrT T GrA AT CrT CC ArG TA and anti-
 .sense, G CTCTA G A A A G rA A A G A TCTG
 .  .  .  .  .GrA GT GrT GC GrA GC GrA TC- GrArC A
 .GrT CCA. RNA was isolated from rat choroid
plexus and rat brain using Trizolw reagent, according
to the manufacturer’s protocol. cDNA was generated
from the RNA using a SuperScripte preamplification
 .kit GIBCO-BRL . Polymerase chain reaction was
performed with the cDNAs and oligonucleotide
primers, using Taq DNA-polymerase Boehringer
.Mannheim . Briefly, denaturation was performed for
3 min at 948C; followed by 40 cycles each of 30 s at
948C, 30 s at 558C and 30 s at 728C. Finally, 2 cycles
were performed at 728C for 7 min.
2.4. Data analysis
The uptake of GABA into the choroid plexus is
expressed as a volume of distribution V , mlrg dryd
.tissue , calculated from the following equation
w x23,24 :
Vd
3w xdpm H GABA in choroid plexusrg of choroid plexus
s 3w xdpm H GABA in uptake mediumrml of uptake medium
14w xdpm C mannitol in choroid plexusrg of choroid plexus
y 14w xdpm C mannitol choroid plexusrml of uptake medium
1 .
For Michaelis–Menten studies, the initial rate of
GABA uptake is expressed as nmolrg dry choroid
plexus tissue per minute and plotted against the con-
centration of GABA. The data were fit to the follow-
ing equation:
V P CmaxRates 2 .
K qCm
where V is the maximal rate of uptake, K ismax m
concentration of GABA at which the rate of uptake is
50% of the maximal rate and C is the concentration
of GABA in the uptake medium. The parameters
were estimated using a non-linear regression program
w on Minim 3.0.8 obtained from Dr. R.D. Purves,
.University of Otago, New Zealand .
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Inhibition of Naq-GABA uptake by various test
compounds was evaluated by estimation of IC val-50
ues: the data were fit to the following four-parameter
logistic function using a non-linear fitting routine on
Minim 3.0.8:
V yV .d ,0 d ,nsV s qV 3 .nd d ,ns1q CrIC .50
where V is the volume of distribution of GABA ind
the choroid plexus; V is the volume of distributiond,0
of GABA in the absence of inhibitor and in the
presence of an inwardly directed Naq-gradient; V ,d,ns
the non-specific diffusional component, is the volume
of distribution of GABA in the absence of a Naq
gradient; C is the concentration of inhibitor in the
uptake mixture; and n is the Hill coefficient. The
IC of GABA in inhibiting Naq-stimulated taurine50
uptake was computed in a manner similar to that
described for GABA.
For each data point, 3–5 measurements were made
per experiment; between one and five experiments
 .were performed see figure legends . Data are pre-
sented as mean"SE of all determinations. All pa-
rameter estimates Michaelis–Menten and IC stud-50
.ies , which were generated using non-linear regres-
 .sion Minim 3.0.8 , are expressed as mean"SD of
the estimates. Means were compared using unpaired
Student’s t-test or one-way ANOVA and a probabil-
ity, P, of less than 0.05 was considered significant.
2.5. Materials
w3 x  .H Taurine specific activity: 21.9 Cirmmol and
w3 x  .H GABA specific activity: 88.4 Cirmmol were
obtained from Du Pont–New England Nuclear Bos-
. w14 xton, MA . C Mannitol was obtained from Moravek
 .Biochemicals Brea, CA . Guvacine, nipecotic acid,
 .OH-nipecotic acid hydroxy-nipecotic acid and
w x4,5,6,7-tetrahydroisoxazolo 4,5-c pyridin-3-ol
 .  .THPO were from RBI Natick, MA . All other
chemicals were purchased from Sigma St. Louis,
.MO . Cytoscint ES scintillation fluid was obtained
 .from ICN Irvine, CA . New Zealand white rabbits
 .2–3 kg were purchased from Nitabell Rabbitry
 .Hayward, CA .
3. Results
3.1. Time dependence
Uptake of GABA into ATP-depleted tissue pieces
was examined in the presence and absence of an
q  .inwardly-directed Na gradient Fig. 1 . A distinct
‘‘overshoot’’ phenomenon, typical of Naq-driven up-
take in ATP-depleted tissue preparations, was ob-
served in the presence of an initial Naq gradient.
Uptake in the presence of the Naq gradient increased
linearly as a function of time, until 2.5 min. It
 .reached a maximum at 15 min V s27.7"2.9 mlrgd
 .and then declined at 30 min V s8.58"2.01 mlrg .d
Uptake at 30 min was not significantly different from
that at 60 min, suggesting that an equilibrium value
of uptake was reached by 30 min.
GABA uptake in the presence of an inwardly-di-
rected Naq gradient was significantly higher than
that when Naq was present in equal concentration
 .inside and outside the tissue 120 mM , at all time
 . qpoints studied Fig. 1 . In addition, absence of Na
Fig. 1. Temporal profile of GABA accumulation in ATP-depleted
 .rabbit choroid plexus. Uptake expressed as V of GABA wasd
determined at 378C. Points represent means"SE of data obtained
from two separate experiments, each performed in quadruplicate.
Uptake at all time points in the presence of a Naq-gradient was
significantly greater than that in the absence of Naq and the
q  .absence of a Na gradient P - 0.001 . Key: 120 mM
q  .inwardly-directed Na gradient filled circles ; 120 mM equal
q  .K inside and outside of the tissue open circles ; 120 mM equal
q  .Na inside and outside of the tissue open diamonds .
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 qfrom the reaction mixture equal K inside and out-
.side, 120 mM resulted in an uptake that was not
significantly different from that when equal Naq was
present inside and outside the tissue, at all time points
studied. These data suggest that a Naq-gradient can
drive the uptake of GABA in the choroid plexus.
3.2. Ion dependence
Replacement of Naq with choline in the uptake
mixture abolished GABA uptake 5.08"0.58 vs.
.0.17"0.05 mlrg, mean"SE, P-0.001 indicating
a strong Naq-dependence. Replacement of Cly with
SCNy, NOy or Bry resulted in a partial attenuation3
of transport which was, however, insignificant 80,
. 68 and 61% of control uptake, respectively Table
.1 . When gluconate was used as the anion in place of
Cly, there was a complete loss of Naq-dependent
GABA uptake 5.08"0.58 vs y0.04"0.04 mlrg,
.mean"SE, P-0.001 . These results suggest a
moderately selective anion requirement for Naq–
GABA transport in the rabbit choroid plexus.
3.3. Concentration dependence
 .The initial rate of uptake of GABA at 1 min was
measured as a function of concentration in the pres-
ence of an inwardly-directed Naq gradient. The rate
of uptake increased initially with increasing substrate
concentration and then achieved a plateau in a man-
 .ner consistent with saturable kinetics Fig. 2 . The
data were fitted to the Michaelis–Menten equation
describing a single saturable component. The esti-
 .mated V and K mean"SD were 409"43max m
nmolrg per min and 37"9 mM, respectively. The
Fig. 2. Concentration dependency of Naq-driven GABA uptake
in ATP-depleted choroid plexus. Uptake at 1 min in nmolrg
tissue was measured at 378C in the presence of a Naq gradient
 .120 mM . Points represent the mean"SE of between 1 to 3
experiments, each performed in triplicate or quadruplicate. GABA
uptakes at the four highest substrate concentrations were not
 .significantly different from each other P s0.741, ANOVA .
The estimated V and K were 409"43 nmolrg per min andmax m
 .37"9 mM, respectively mean"SD .
uptake values at the 4 highest GABA concentrations
were not significantly different from each other
 .ANOVA, Ps0.741 , indicating that a non-saturable
component was not a major component of GABA
transport into the tissue. Hence, a linear term was not
included in the equation used to fit the data.
3.4. Inhibition
Various compounds previously shown to inhibit
GABA transport in other tissue were tested for their
ability to inhibit GABA transport in choroid plexus
Table 1
Ion-dependence of GABA uptake
 .Condition V of GABA mlrg % of control P value compared to controld
q y  .  .Na , Cl control 5.08"0.58 2 100 –
q y  .Na , SCN 4.06"0.28 2 80 n.s.
q y  .Na , NO 3.49"0.35 2 68 n.s.3
q y  .Na , Br 3.13"0.67 1 61 n.s.
q y  .Na , Gluconate y0.04"0.04 2 0 -0.001
q y  .Choline , Cl 0.17"0.05 2 3 -0.001
 .  .  .ATP-depleted choroid plexus pieces were pre-incubated in choline Cl 120 mM , KCl 40 mM and HEPES 15 mM pH 7.4. For uptake
w3 x  .  .  .studies, tissue was incubated with H GABA in either buffer containing NaCl 120 mM , KCl 40 mM and HEPES 15 mM pH 7.4, or
in buffers which were identical except for equimolar replacement of Cly with SCNy, NOy, Bry or gluconatey, or in which Naq was3
q  .replaced with choline . Data represent mean"SE of uptake determined at 1 min ; the number of experiments are indicated in
parentheses. Each experiment was performed in replicates of five; n.s. denotes not significant.
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Fig. 3. Effect of various inhibitors on Naq-driven GABA uptake
 .in ATP-depleted choroid plexus tissue. Uptake mlrg of GABA
 .1 mM was measured at 378C in the presence of various
 .concentrations 0, 25, 100, 300, 500 and 1000 mM of unlabeled
compounds. Key: b-Ala, b-Alanine; HyT, hypotaurine; NA,
nipecotic acid; OH-NA, hydroxy-nipecotic acid. Points represent
mean"SE of between 1 and 4 experiments, each performed in
quadruplicate. Where error bars are not visible, they are encom-
passed within the point. Points are connected by a simple linear
spline. See Table 1 for a summary of these and other results.
tissue pieces. All potential compounds were tested at
various concentrations 0, 25, 100, 300, 500 and 1000
.  .mM , and IC values mean"SD were obtained50
Table 2
Inhibitor sensitivity of GABA uptake in rabbit choroid plexus
 .  .Inhibitor IC mM K mM50 i
b-Alanine 22.9"18.1 22.2"17.5
Hypotaurine 21.9"17.3 21.2"16.7
Nipecotic acid 244"113 236"109
OH-Nipecotic acid 284"128 275"124
Guvacine 565"208 547"201
THPO )1 mM )1 mM
L-DABA )1 mM )1 mM
Taurine )1 mM )1 mM
Betaine )1 mM )1 mM
L-Alanine )1 mM )1 mM
q  . w3 xFor IC estimates, the Na -driven uptake 1 min of H GABA50
was measured in the presence of various inhibitors. Each in-
hibitor was tested at 0, 25, 100, 300, 500 mM and 1 mM. Uptake
values, which were corrected for non-specific Naq-independent
uptake, were pooled from between 1–5 experiments and fitted to
the equation as described in Section 2. Each experiment was
performed in quadruplicate. IC and K values are the mean"50 i
SD of the estimate; Fig. 3 depicts some of the data. To allow
comparison with other studies, K values were generated fromi
IC determinations using the Cheng and Prusoff relationship50
w x  .41 , which assumes competitive inhibition: K s IC r 1qS ,i 50
where Ssconcentration of GABArK of GABA.m
Fig. 4. Effect of GABA on Naq-driven taurine uptake in ATP-de-
 . .pleted choroid plexus tissue. Uptake mlrg of taurine 25 mM
was measured at 378C in the presence of various concentrations
 .25, 50, 100, 250, 500, 1000, 2000 and 5000 mM of unlabeled
GABA. Points represent mean"SE of 1 experiment, performed
in quadruplicate. The curve represents the best fit to the data and
 .was generated using the equation for IC see Section 2 . The50
IC was estimated to be 230 mM.50
 . Fig. 3, Table 2 . Hypotaurine IC s21.9"17.350
.  .mM and b-alanine IC s22.9"18.1 mM were50
potent inhibitors of Naq-driven GABA uptake in
choroid plexus tissue pieces. Nipecotic Acid IC s50
. 244"113 mM and OH-nipecotic acid IC s28450
."128 mM were moderately potent in their ability to
q  .inhibit Na -driven GABA uptake. Betaine, L- 2,4 -
 .diaminobutyric acid L-DABA , guvacine and THPO
showed weak inhibitory activity, with IC values of50
)1 mM. Neither taurine nor L-alanine, an isomer of
b-alanine, significantly inhibited GABA uptake IC50
.)1 mM .
The effect of GABA on the Naq-dependent uptake
 .of taurine 25 mM into the tissue pieces was deter-
mined at 15 min. GABA inhibited taurine uptake
 .with an IC value of 230 mM Fig. 4 . Since an50
inhibitor may not necessarily be a substrate of the
transporter, further studies are required to determine
if GABA is a substrate of the Naq-taurine transporter
in choroid plexus.
3.5. RT–PCR
RT–PCR with primers specific to GAT-3, resulted
in the amplification of a band of predicted size from
the rat brain but not from the choroid plexus data not
.shown . Identical results were obtained using primers
degenerate for GAT-1, which were designed to am-
 .plify both GAT-1 and GAT-3 data not shown .
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4. Discussion
GABA is the dominant inhibitory neurotransmitter
in the brain and is present throughout the central
nervous system. The neurotransmitter actions of
GABA in the synaptic cleft are terminated by its
reuptake via Naq and Cly coupled transporters; both
neuronal and glial cells express one or more members
w xof this closely related family of transporters 3–7 .
Imbalances in GABA function in the brain have been
w xassociated with psychiatric 26 and neurological dis-
w xeases 27,28 . Studies with post-mortem human brains
suggest that an increased level of expression of GABA
w xtransporters may be involved in schizophrenia 29 . In
w xvarious species, including humans 30 , GABA trans-
porters have been implicated in epilepsy and are an
active target of drug design efforts for the disease
w x31–35 . Inhibitors of GABA transporters have
demonstrated usefulness in animal models of seizures
w x36–38 presumably by sustaining the concentration
of GABA in the synaptic cleft. Our finding of a
GABA transporter in the choroid plexus of the brain
suggests an additional mechanism that may govern
the disposition of GABA in the brain.
In vivo studies suggest that the transfer of GABA
from blood to the CSF and the disposition of GABA
in the CSF is governed by a carrier-mediated process
w x18 . An early, preliminary study reported saturable
w xuptake of GABA in the choroid plexus of the cat 19 .
However, neither the driving force for GABA trans-
port in the choroid plexus nor the specificity of the
observed transport process was determined. Here, we
provide evidence for a Naq-dependent GABA trans-
 .porter CP–GABA transporter in the choroid plexus
of the rabbit brain. Following ATP-depletion of the
tissue, we determined that GABA uptake was driven
q  .by an initial inwardly-directed Na -gradient Fig. 1 .
This Naq-gradient-dependent uptake is characteristic
of concentrative accumulation of a substrate by the
tissue, and it is similar to that seen for GABA uptake
in other tissue. As with other GABA transporters,
Cly supported GABA transport optimally; replace-
ment of Cly with gluconate completely abolished
transport. However, SCNy, NOy and Bry were also3
able to sustain GABA transport, suggesting that Cly
is not absolutely necessary for GABA transport in the
choroid plexus. Similar results have been obtained for
q w xNa -GABA transport in the retina 10 . In contrast,
while Cly replacement has been less well studied for
the Naq-GABA transporters in the brain, they gener-
ally show a strong requirement for Cly and in some
y w xcases Br 3,4,6 . These results suggest that the
CP–GABA transporter may be similar to the GABA
transporter in the retina. In this study, the estimated
 .K 37"8 mM indicates that the affinity of them
GABA transporter in the choroid plexus for GABA is
similar to that of other GABA transporters in the
w x w xbrain 3,4,6,7 and other tissues 10,13,14 . We note
that the K for GABA reported by Lorenzo K sm m
.230 mM in the cat choroid plexus is considerably
w xhigher than the one we obtained in this study 19 .
The reason for this discrepancy is not clear; it is
possible that it results from methodological or species
differences.
To determine the selectivity of the CP–GABA
transporter, we examined the potency of various com-
pounds known to inhibit GABA transport in other
tissues. Of the compounds tested, b-alanine IC s50
.  .22.9 mM and hypotaurine IC s21.9 mM were50
the most potent, whereas L-DABA and betaine were
not able to effectively inhibit Naq-driven GABA
transport in choroid plexus. These data suggest that
the CP–GABA transporter is most similar to GAT-
3rGAT-B, which is sensitive to b-alanine but insen-
sitive to L-DABA GAT-1 is insensitive to b-alanine
.and GAT-2 is sensitive to L-DABA . However, the
 .anion requirements Table 1 suggest that there may
be functional differences in the two transporters.
Finally, the choroid plexus transporter is also differ-
ent from the GABA-transporting renal epithelial
transporter, BGT, by virtue of its refractoriness to
betaine.
Because hypotaurine and b-alanine, both potent
inhibitors of Naq-GABA uptake in the rabbit choroid
plexus, also inhibit taurine uptake via the Naq-taurine
transporter in the choroid plexus, we asked if both
uptake processes were mediated via the same trans-
porter. The finding that GABA inhibits the uptake of
 .taurine Fig. 4, IC s230 mM , but taurine does not50
 .inhibit GABA uptake significantly Table 2 , sug-
gests that the Naq-GABA transporter, which we have
characterized in the choroid plexus, is distinct from
the Naq-taurine transporter.
RT–PCR of rat brain RNA using oligonucleotide
w xprobes degenerate for the rat GAT-1 5 resulted in
amplification of a band of predicted size data not
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.shown . Similarly probes specific for GAT-3rGAT-B
resulted in the amplification of the predicted band
 .data not shown . We did not observe amplification
of corresponding bands, with either set of probes,
when RNA from rat choroid plexus was used. These
data suggest that the rat choroid plexus may not
express a GABA transporter similar to GAT-1 or
GAT-3rGAT-B. However, alternative RT–PCR con-
ditions may be necessary to identify GAT-1 or GAT-3
mRNA transcripts in the choroid plexus.
The presence of a GABA receptor in the choroidA
plexus epithelium of the rat has been documented
w x39 ; in vivo studies indicate that benzodiazepine
ligands reduce the secretion rate of the CSF by up to
w x50% 40 . The concomitant presence of a GABA
transporter is consistent with the suggested involve-
ment of GABA-ergic mechanisms in modulation of
CSF production. Furthermore, the transporter for
GABA in the choroid plexus may play a role in
maintaining homeostasis of GABA in the CSF, and
ultimately the brain. Such a transporter may also be
important in the targeting of GABA analogs to the
central nervous system.
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